SCHEMBL4835546

SCHEMBL4835546

COC(c1coc(-c2ccc(F)cc2)n1)C1(COCc2cccc(C)c2C(=O)O)CC=CCC1

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.32
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.30
TSHR P16473 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4829980 0.90 S1PR1 (0.33) PPARALMNAGAATSHRKMT2A
SCHEMBL4827340 0.88 PPARA (0.33) PPARALMNAGAATSHRKMT2A
SCHEMBL4835550 0.81 LMNA (0.38) PPARALMNAGAATSHRKMT2A
SCHEMBL4829988 0.74 HPGD (0.41) PPARALMNAGAATSHRKMT2A
SCHEMBL4827344 0.73 LMNA (0.41) PPARALMNAGAATSHRKMT2A
SCHEMBL4826863 0.72 HPGD (0.35) PPARALMNAGAATSHRKMT2A
SCHEMBL6487455 0.70 PPARA (0.38) PPARALMNAGAATSHRKMT2A
SCHEMBL3294431 0.69 PPARA (0.44) PPARALMNAGAATSHRKMT2A
SCHEMBL4835194 0.69 HPGD (0.46) PPARALMNAGAATSHRKMT2A
SCHEMBL14106717 0.69 HPGD (0.46) PPARALMNAGAATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7399777-B2 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-07-15 US disclosed
EP-1425014-B1 DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS SANOFI AVENTIS DEUTSCHLAND (DE) 2006-12-13 EP disclosed
US-20050267177-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-12-01 US disclosed
US-6884812-B2 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-04-26 US disclosed
US-20040122069-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-06-24 US disclosed
EP-1425014-A1 DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS Aventis Pharma Deutschland GmbH (DE) 2004-06-09 EP disclosed
US-20030144332-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-07-31 US disclosed
WO-2003020269-A1 DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144332-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals PNLIP, LIPC, APOB PPARA 383/4885LMNA 1312/4885GAA 565/4885
US-20040122069-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals PNLIP, LIPC, APOB PPARA 365/4885LMNA 1215/4885GAA 559/4885
US-20050267177-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals PNLIP, LIPC, LIPA PPARA 345/4885LMNA 1198/4885GAA 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.